Eilmeldung
TRGaziantep'te Milletvekili Melih Meriç'e Bıçaklı SaldırıTRİranlı eski Cumhurbaşkanı Hatemi'den ABD ile imzalanan mutabakata destekARتسليم ضابط سوري سابق، وتوترات إسرائيلية تركية، وعمليات واسعة في الضفة الغربيةRUDenmark deploys military conscripts to Greenland amid US annexation threatsUSHackers Steal Data of Over 3.75 Million in CareCloud BreachEUCentral African Republic Gold Mine Landslide Kills At Least 100UKReigning FPL Champion Erik Ibsen Shares Winning StrategiesARالعلا يفوز على الفتح في كأس الملك، وبيسيرو: فوز مستحق، لكننا لم نحقق شيئًا بعدCN七夕夜·情定望宸:杭州市拱墅区第十一届大运河集体婚礼暨巧山乞巧民俗活动CN馬來西亞首相安華發表貶損台灣主權言論,強化國防備應美國菲律賓軍事前哨TRGaziantep'te Milletvekili Melih Meriç'e Bıçaklı SaldırıTRİranlı eski Cumhurbaşkanı Hatemi'den ABD ile imzalanan mutabakata destekARتسليم ضابط سوري سابق، وتوترات إسرائيلية تركية، وعمليات واسعة في الضفة الغربيةRUDenmark deploys military conscripts to Greenland amid US annexation threatsUSHackers Steal Data of Over 3.75 Million in CareCloud BreachEUCentral African Republic Gold Mine Landslide Kills At Least 100UKReigning FPL Champion Erik Ibsen Shares Winning StrategiesARالعلا يفوز على الفتح في كأس الملك، وبيسيرو: فوز مستحق، لكننا لم نحقق شيئًا بعدCN七夕夜·情定望宸:杭州市拱墅区第十一届大运河集体婚礼暨巧山乞巧民俗活动CN馬來西亞首相安華發表貶損台灣主權言論,強化國防備應美國菲律賓軍事前哨
Newsgather

semaglutid

Stabil24 Meldungen9 QuellenZuletzt aktualisiert: vor 6 Tagen

Neueste Meldungen

GLP-1 Drug Implant Aims to Solve Long-Term Weight Loss Maintenance
In Entwicklung
Gesundheit·11.7.2026KI-Zusammenfassung

GLP-1 Drug Implant Aims to Solve Long-Term Weight Loss Maintenance

Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.

C
CNBC US Markets
8 Min. Lesezeit
Reposição de medicamentos: O que são e como salvam vidas
In Entwicklung
Gesundheit·16.6.2026KI-Zusammenfassung

Reposição de medicamentos: O que são e como salvam vidas

O reposicionamento de medicamentos, que consiste em encontrar novos usos para fármacos já existentes, tem se mostrado uma estratégia eficaz e econômica para salvar vidas, especialmente em crises de saúde como a da COVID-19. Medicamentos como a dexametasona e o baricitinibe foram reaproveitados para tratar a inflamação em pacientes com coronavírus, salvando milhares de vidas. A Comissão Europeia planeja expandir essa abordagem para a busca de tratamentos contra o câncer. Exemplos históricos incluem o raloxifeno para prevenção de câncer de mama, a talidomida para mieloma múltiplo e o Viagra (sildenafil) para disfunção erétil, originalmente desenvolvido para doenças cardiovasculares. A tendência de reaproveitamento de medicamentos levanta questões sobre seus verdadeiros prós e contras, cujas respostas podem levar anos para serem totalmente compreendidas.

G
G1
6 Min. Lesezeit
Semaglutide Shows Promise for Patients Failing Bariatric Surgery, Oats Aid Diabetes Control, and Diet Impacts Stress
Gesundheit
25.5.2026KI-Zusammenfassung

Semaglutide Shows Promise for Patients Failing Bariatric Surgery, Oats Aid Diabetes Control, and Diet Impacts Stress

A UK study suggests Semaglutide may benefit patients unresponsive to bariatric surgery. Separately, oats are highlighted for their role in managing blood sugar for diabetics due to soluble fiber. Additionally, experts warn that processed foods, refined carbs, and high sodium/saturated fat diets can exacerbate stress hormone (cortisol) levels.

ا
الشرق الأوسط
6 Min. Lesezeit
Dr Reddy's Laboratories First to Get Health Canada Approval for Generic Semaglutide Injection
NACHRICHT
29.4.2026KI-Zusammenfassung

Dr Reddy's Laboratories First to Get Health Canada Approval for Generic Semaglutide Injection

Dr Reddy's Laboratories has become the first company to receive Health Canada approval for generic semaglutide injection, covering 2 mg/pen and 4 mg/pen dosages. The approval, granted ahead of the regulatory review target date, marks a significant milestone in the company's GLP-1 journey and aims to expand access to affordable diabetes treatments for Canadian patients, where approximately 3.9 million people (9.7% of the population) live with diagnosed diabetes.

E
Economic Times
1 Min. Lesezeit
Dr Reddy's First to Get Generic Semaglutide Approval in Canada
Gesundheit
29.4.2026KI-Zusammenfassung

Dr Reddy's First to Get Generic Semaglutide Approval in Canada

Dr Reddy's Laboratories has received notice of compliance from Health Canada for its generic semaglutide injection, becoming the first company to receive market authorization for this diabetes treatment in Canada. The approval covers 2 mg/pen and 4 mg/pen dosages. The company is preparing to launch the medication to provide Canadian patients with access to this therapy.

E
Economic Times
1 Min. Lesezeit